<a href="https://laohu8.com/S/LTRN">Lantern Pharma Inc.</a> Announces Promising Results from HARMONIC Trial as Lung Cancer Patient Achieves Durable Complete Response with LP-300
Lantern Pharma Inc. (NASDAQ: LTRN) has announced notable clinical observations from its Phase 2 HARMONIC™ clinical trial. A 70-year-old patient with advanced non-small cell lung cancer (NSCLC), who has never smoked, has achieved a durable complete response in their target cancer lesions following treatment with LP-300 in combination with standard-of-care chemotherapy. This patient continues to show sustained survival benefits nearly two years after the treatment. LP-300, developed using Lantern's proprietary RADR® AI platform, is being evaluated for its therapeutic potential in never-smokers with advanced NSCLC who have progressed after treatment with tyrosine kinase inhibitors. Results from this study have already been presented, showing promise for LP-300 as a treatment option in this patient population.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250616197862) on June 16, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。